资源类型：
会议/期刊
收录情况：
◇ SCIE
◇ CPCI(ISTP)
文章类型：
会议摘要
作者：
Song, Yuqin
*
;
Liu, Yanyan
;
Li, Zhi-Ming
;
Li, Lanfang
;
Su, Hang
;
Jin, Zhengming
;
Zuo, Xuelan
;
Wu, Jianyuan
;
Zhou, Hui
;
Li, Kunyan
;
He, Chuan
;
Zhou, Jianfeng
;
Qi, Junyuan
;
Hao, Siguo
;
Cai, Zhen
;
Li, Yijing
;
Wang, Weiwei
;
Zhang, Xiaojing
;
Zou, Jianjun
;
Zhu, Jun
;
单位：
[1]Peking Univ Canc Hosp & Inst, Dept Lymphoma, Key Lab Carcinogenesis & Transit Res, Minist Educ, Beijing, Peoples R China
[2]Henan Canc Hosp, Lymphat Comprehens Internal Med Ward, Zhengzhou, Peoples R China
河南省肿瘤医院
[3]Sun Yat Sen Univ, Canc Ctr, Med Oncol, Guangzhou, Peoples R China
[4]Tianjin Med Univ, Canc Inst & Hosp, Dept Lymphoma, Tianjin, Peoples R China
[5]Peoples Liberat Army Gen Hosp, Med Ctr 5, Beijing, Peoples R China
[6]Soochow Univ, Affiliated Hosp 1, Dept Hematol, Suzhou, Peoples R China
[7]Wuhan Univ, Zhon gnan Hosp, Dept Hematopathol, Wuhan, Peoples R China
[8]Wuhan Univ, Clin Trial Ctr, Zhongnan Hosp, Wuhan, Peoples R China
[9]Hunan Canc Hosp, Changsha, Peoples R China
[10]Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp, Early Clin Trial Ctr Hunan Canc Hosp, Changsha, Peoples R China
[11]Sichuan Univ, West China Hosp, Dept Hematopathol, Chengdu, Peoples R China
四川大学华西医院
[12]Tongji Hosp Tongji Med Coll Hust, Dept Hematol, Wuhan, Peoples R China
内科学系
血液内科
华中科技大学同济医学院附属同济医院
[13]Chinese Acad Med Sci, Blood Dis Hosp, GCP ward, Tianjin, Peoples R China
[14]Shanghai Jiao Tong Univ Sch Med, Xinhua Hosp Affiliated, Dept Hematol, Shanghai, Peoples R China
[15]Zhejiang Univ, Bone Marrow Transplantat Ctr, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China
浙江大学医学院附属第一医院
[16]Jiangsu Hengrui Pharmaceut Co Ltd, Clin Res Dev, Shanghai, Peoples R China
[17]Jiangsu Hengrui Pharmaceut Co Ltd, Shanghai, Peoples R China
[18]Peking Univ Canc Hosp & Inst, Beijing, Peoples R China
出处：
JOURNAL OF CLINICAL ONCOLOGY.2022,40(16):
ISSN：
0732-183X
基金：
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
WOS：
WOS:000863680301986
中科院(CAS)分区：
出版当年[2021]版：
大类
|
1 区
医学
小类
|
1 区
肿瘤学
最新[2025]版：
大类
|
1 区
医学
小类
|
1 区
肿瘤学
影响因子：
42.1
最新[2023版]
37.4
最新五年平均
44.544
出版当年[2020版]
33.883
出版当年五年平均
32.956
出版前一年[2019版]
50.739
出版后一年[2021版]
第一作者：
Song, Yuqin
推荐引用方式(GB/T 7714)：
Song Yuqin,Liu Yanyan,Li Zhi-Ming,et al.SHR2554, an enhancer of zeste homolog 2 (EZH2) inhibitor, in relapsed or refractory (r/r) mature lymphoid neoplasms: A first-in-human phase 1 study[J].JOURNAL OF CLINICAL ONCOLOGY.2022,40(16):
APA：
Song, Yuqin,Liu, Yanyan,Li, Zhi-Ming,Li, Lanfang,Su, Hang...&Zhu, Jun.(2022).SHR2554, an enhancer of zeste homolog 2 (EZH2) inhibitor, in relapsed or refractory (r/r) mature lymphoid neoplasms: A first-in-human phase 1 study.JOURNAL OF CLINICAL ONCOLOGY,40,(16)
MLA：
Song, Yuqin,et al."SHR2554, an enhancer of zeste homolog 2 (EZH2) inhibitor, in relapsed or refractory (r/r) mature lymphoid neoplasms: A first-in-human phase 1 study".JOURNAL OF CLINICAL ONCOLOGY 40..16(2022)
医学